<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840579</url>
  </required_header>
  <id_info>
    <org_study_id>3475-011</org_study_id>
    <secondary_id>132249</secondary_id>
    <nct_id>NCT01840579</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)</brief_title>
  <official_title>A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study using pembrolizumab (MK-3475) will be done in 5 parts. In Part A, successive
      participant cohorts with advanced solid tumors will receive pembrolizumab to assess the
      safety and tolerability of monotherapy. In Parts B, C, and D, participants with advanced
      non-small cell lung cancer (NSCLC) will receive pembrolizumab in combination with either
      cisplatin/pemetrexed or carboplatin/pemetrexed (Part B); with either carboplatin/paclitaxel
      or carboplatin/nab-paclitaxel (Part C); or with ipilimumab (Part D) by non-random assignment
      to assess the safety and tolerability of the combination therapy. In Part E, participants
      with untreated Extensive-disease (ED) Small Cell Lung Cancer (SCLC) will receive
      pembrolizumab in combination with either cisplatin/etoposide, carboplatin/etoposide, or
      cisplatin/etoposide with prophylactic use of granulocyte colony-stimulating factor (lasting
      G-CSF [pegfilgrastim]) by non-random assignment to assess the safety and tolerability of the
      combination therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 26, 2013</start_date>
  <completion_date type="Anticipated">April 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (first dose up to 6 weeks)</time_frame>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Carboplatin/Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Carboplatin/Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Carboplatin/Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Cisplatin/Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Carboplatin/Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part E, participants receive IV Pembrolizumab 200 mg + IV IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab+Cisplatin/Etoposide+G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting G-CSF (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks for up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab 2 mg/kg</intervention_name>
    <description>Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)</description>
    <arm_group_label>Pembrolizumab 2 mg/kg</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab 10 mg/kg</intervention_name>
    <description>Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)</description>
    <arm_group_label>Pembrolizumab 10 mg/kg</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab 200 mg</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Pemetrexed</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Paclitaxel</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Pembrolizumab+Ipilimumab</arm_group_label>
    <arm_group_label>Pembrolizumab+Cisplatin/Etoposide</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Etoposide</arm_group_label>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin 75 mg/m^2</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_label>Pembrolizumab+Cisplatin/Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed 500 mg/m^2</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Cisplatin/Pemetrexed</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Pemetrexed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 5 mg/mL/min</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Carboplatin/Pemetrexed</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 6 mg/mL/min</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Carboplatin/Paclitaxel</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 200 mg/m^2</intervention_name>
    <description>Administered as an IV infusion on Day 1 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Carboplatin/Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel 100 mg/m^2</intervention_name>
    <description>Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Carboplatin/Nab-paclitaxel</arm_group_label>
    <other_name>ABRAXANE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab 1 mg/kg</intervention_name>
    <description>Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)</description>
    <arm_group_label>Pembrolizumab+Ipilimumab</arm_group_label>
    <other_name>YERVOY®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide 100 mg/m^2</intervention_name>
    <description>Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle</description>
    <arm_group_label>Pembrolizumab+Cisplatin/Etoposide</arm_group_label>
    <arm_group_label>Pembrolizumab+Carboplatin/Etoposide</arm_group_label>
    <other_name>TOPOSAR®, VEPESID®, ETOPOPHOS®, EPOSIN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF (pegfilgrastim) 3.6 mg</intervention_name>
    <description>Administered as a subcutaneous injection on Day 4 of Cycle 1</description>
    <arm_group_label>Pembrolizumab+Cisplatin/Etoposide+G-CSF</arm_group_label>
    <other_name>Neulasta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In Part A: has a histological or cytological diagnosis of solid tumor, progressive
             metastatic disease, or progressive locally advanced disease not amenable to local
             therapy

          -  In Part B, C, and D: has a histologically- or cytologically-confirmed diagnosis of
             NSCLC (Stage IIIB/IV) and are naïve to systemic therapy

          -  In Part C: has a histologically- or cytologically-confirmed diagnosis of squamous
             cancer

          -  In Part E: has a histologically- or cytologically-confirmed diagnosis of SCLC (ED
             stage) and are naïve to systemic therapy

          -  Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Has adequate organ function

          -  Female participants of reproductive potential must not be pregnant (negative urine or
             serum human chorionic gonadotropin test within 72 hours of study start)

          -  Female and male participants of reproductive potential must agree to use adequate
             contraception throughout the study period and for up to 120 days after the last dose
             of study therapy and for up to 180 days after the last dose of chemotherapeutic agents

        Exclusion criteria:

          -  Has had cancer therapy within 2 weeks (Part E) or 4 weeks (Parts A, B, C, and D) prior
             to the first dose of study therapy, or not recovered from the adverse events of agents
             administered more than 4 weeks prior to the first dose of study therapy.

               -  Part A: Chemotherapy, radiation therapy, biological therapy or kinase inhibitors

               -  Parts B, C, D and E: Radiation therapy

          -  For Part B: has a histological diagnosis of squamous cancer

          -  Is currently participating or has participated in a study with an investigational
             agent or using an investigational device within 30 days of first dose of study therapy

          -  Is expected to require any other form of antineoplastic therapy while on study

          -  Is on chronic systemic steroid therapy within two weeks prior to the first dose of
             trial treatment or on any other form of immunosuppressive medication

          -  For Part C: Has pre-existing peripheral neuropathy that is ≥ Grade 2 by Common
             Terminology Criteria for Adverse Events version 4 criteria

          -  Has interstitial lung disease detected by chest CT, or a history of pneumonitis that
             required oral or intravenous glucocorticoids to assist with management. Lymphangitic
             spread of the NSCLC is not exclusionary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest New Drugs. 2016 Jun;34(3):347-54. doi: 10.1007/s10637-016-0347-6. Epub 2016 Mar 22.</citation>
    <PMID>27000274</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

